trilaciclib Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Trilaciclib is indicated
to reduce the frequency of chemotherapy-induced bone marrow suppression
in adults receiving certain types of chemotherapy for extensive-stage
(when the cancer has spread beyond the lungs) small cell lung cancer.
Trademarks
Cosela
TM
Nebenwirkungen
Trilaciclib helps reduce the bone marrow suppression side effect of chemotherapy, but it may also come with its own side effects, including low white blood cell counts, fatigue, nausea and hair loss.
Synthese
The synthesis of trilaciclib is as follows:
Intermediate 2 (21.1 g, 70 mmol) and 1-methyl-4-(6-aminopyridin-3-yl)piperazine (13.4 g, 70 mmol) were added to a 100 mL vacuum tube and reacted at 230° C. for 3 h.After the reaction, 300 mL of ethyl acetate was added, washed with water (120 mL) and saturated brine (120 mL) successively, dried with anhydrous sodium sulfate and filtered, the obtained solution was evaporated under reduced pressure to remove the solvent, and the obtained residue was recrystallized with ethanol, 27.5 g of Trilaciclib was obtained with a purity of 99% and a yield of 88%.
Lager
Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
trilaciclib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
